AI-Guided Molecular Design for Accelerating Small-Molecule Drug Discovery

Abstract

The pervasive productivity crisis in pharmaceutical R&D, encapsulated by Eroom's Law, demands a fundamental transformation in drug discovery. Artificial intelligence emerges as a pivotal solution, not by replacing human expertise, but by forging a synergistic partnership with medicinal chemists. By leveraging vast, curated biological and chemical data, sophisticated molecular representations, and core AI paradigms— including predictive modeling, unsupervised exploration, and generative design—AI is re-engineering the discovery pipeline. It accelerates target identification, enables billion-compound virtual screening, and drives the de novo design of optimized lead candidates. Critically, AI-powered predictive ADMET and safety profiling frontload risk assessment, aiming to reduce costly late-stage attrition. This integration of AI across the workflow—from target to candidate—promises to compress timelines, lower costs, and enhance the precision of therapeutic design. Ultimately, the AI-guided paradigm represents a necessary and powerful evolution, positioning the field to finally bend the curve of Eroom's Law and deliver innovative medicines to patients with unprecedented efficiency.